Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China

Cancer Detection and Prevention

Volumn 27, Issue 2, 2003, Pages 132-138

  Hu, Nan ^a   Li, Wen Jun ^b   Su, Hua ^c   Wang, Chaoyu ^a   Goldstein, A M ^a   Albert, P S ^a   Emmert Buck, M R ^a   Kong, Li Hui ^b   Roth, M J ^a   Dawsey, S M ^a   He, Li Ji ^a,d   Cao, Shu Fen ^b   Ding, Ti ^b   Giffen, Carol ^a,d,e   Taylor, P R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SHANXI CANCER HOSPITAL   (China)

^c National Vaccine and Serum Institute   (China)

^d Yangcheng Cancer Hospital   (China)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

BRCA2; Cancer risk; China; Esophageal cancer; Polymorphisms; TP53

Indexed keywords

EID: 0037254305     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(03)00031-X     Document Type: Article

References (31)

1. Li MH, Li P, Li PR. Recent progress in research on esophageal cancer in China. Adv Cancer Res 1980;33:173-249.
2. Li JY. Epidemiology of esophageal cancer in China. Natl Cancer Inst Monogr 1982;62:113-20.
3. National Cancer Control Office, Investigation of cancer mortality in China. Beijing: People's Health Publishing House; 1980.
4. National Cancer Control Office, Nanjing Institute of Geography. Atlas of China Mortality in the People's Republic of China. Beijing: China Map Press; 1980.
5. Yang CS. Research on esophageal cancer in China: a review. Cancer Res 1980;40:2633-44.
6. Syrjanen KJ. HPV infections and oesophageal cancer. J Clin Path 2002;55:721-8.
7. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
8. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
9. Vaughn JP, Cirisano FD, Huper G, et al. Cell cycle control of BRCA2. Cancer Res 1996;56:4590-4.
10. National Cancer Control Office. Investigation of cancer mortality in China. Beijing: People's Health Publishing House; 1980.
11. Hu N, Roth M, Polymeropolous M, et al. Identification of novel regions of allelic loss from a genome-wide scan of esophageal squamous cell carcinoma in a high-risk Chinese population. Genes Chromosomes Cancer 2000;27:217-28.
12. Huang J, Hu N, Goldstein AM, et al. A high frequency of allelic loss on chromosome 17p13.3-p11.2 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis 2000;21:2019-26.
13. Li G, Hu N, Goldstein AM, et al. Allelic loss at chromosome 13q11-q13 in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. Genes Chromosomes Cancer 2001;31:390-7.
14. Hu N, Huang J, Emmert-Buck MR, et al. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high risk population in China. Clin Cancer Res 2001;7:883-91.
15. Hu N, Li G, Li WJ, et al. Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. Clin Cancer Res 2002;8:1121-6.
16. Yu MW, Yang SY, Chiu YH, Chang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999;29:697-702.
17. Pierce LM, Sivaraman L, Chang W, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomark Prev 2000;9:1199-204.
18. Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26:362-4.
19. Lee JM, Lee YC, Yang SY, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous cell carcinoma of the esophagus. Int J Cancer 2000;89:458-64.
20. Guimaraes DP, Lu SH, Snijders P, et al. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett 2001;162:231-5.
21. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
22. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 Codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999;5:129-34.
23. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
24. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC. Determination of the allele frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 1994;15:583-7.
25. Jin X, Wu X, Roth J, et al. Higher lung cancer risk for younger Africa-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205-8.
26. Sjalander A, Birgander R, Hallmans G, et al. p53 Polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-6.
27. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 2000;9:1037-42.
28. Malcolm EK, Baber GB, Boyd JC, Stoler MH. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol 2000;13:373-8.
29. Kawaguchi H, Ohno S, Araki K, et al. p53 Polymorphism in human papillomvirus-associated esophageal cancer. Cancer Res 2000;60:2753-5.
30. Pyne MT, Brotherman AR, Ward B, Press D, Hendrickson BC, Scholl T. The BRCA2 genetic variant IVS7 + 2T → G is a mutation. J Hum Genet 2000;45:351-7.
31. Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyl-transferase activity when bound to P/CAF. Oncogene 1998;17:2531-4.